A Russian company is specialized in conducting research, development and production of completed test-systems in the field of biotechnology and molecular genetics. The company developed reagent kits for non-invasive prostate cancer diagnostics based on the technology of real-time polymerase chain reaction and using patient’s urine. The company offers their products under a commercial agency or distribution services agreement.
The Russian company from Ulyanovsk region leads developments in the field of molecular genetic diagnostics in obstetrics and oncology. The production laboratory of the company was certified in 2012, it is fitted with equipment for manufacturing of kits based on the technology of real-time polymerase chain reaction and quality monitoring procedure. The total area of laboratory manufacturing complex – 100 sq.m. Highly professional scientists with medical, biological education, participants of numerous international profile conferences, authors of a large number of scientific publications are on the staff of the company. The company presents laboratory test system for prostate cancer diagnostics based on the technology of real-time polymerase chain reaction and using patient’s urine. Analytical characteristics: Analytical specificity: 100 %; Analytical sensitivity: 100 ribonucleic acid copies; The amounts of total ribonucleic acid suitable for performing studies: min 1 mcg- max 5 mcg; Range of prostate cancer antigen 3 scores that are considered as normal: 35 Using the testing in clinical practice allows to: - take timely measures for prostate cancer treatment; - the best alternative to ultrasonography and invasive testing. The company is interested in finding partners from healthcare sphere to conclude commercial agency agreement, distribution services agreement for introduction and distribution of the company products in medical institution abroad.
Innovations and advantages
The kits have high diagnostic patterns: analytical specificity 100% and analytical sensitivity 100 ribonucleic acid copies. Professional taken sample at hospital, lab or patient home. It is absolutely safe and noninvasive because only a patient’s urine is using. Time to implement test and to get results – 90 minutes The tests are easy-to-use and ready to apply in every polymerase chain reaction laboratory. The tests have passed clinical trials and complied Russian Certificate of Validation. High level of quality, certification of the enterprise on compliance to requirements of the International Organization for Standardization 9001:2008 and Conformité Européenne . Company headhunts gifted and promising specialists and has efficient personnel on all levels of production (4 staff scientists with Doctor of Philosophy). Continuous improvement and development of new products within the strategic directions of development of the enterprise. Advantageous geographical position.
06001005 Diagnostics, Diagnosis
06001009 Gene - DNA Therapy
Market application codes
05001002 In-vitro diagnostics
Intellectual property rights
Comments, number and date of patent
Russian Certificate of Validation (got in 2013) Eurasian patent (got in 2014) Conformité Européenne (confirmed in 2016)
Type of partner sought
Type of partner: SMEs. Field of activity: medical laboratory, cancer centres, private medical centres, distributor of medical equipment for polymerase chain reaction laboratory, genetic researching centers and Institutes. Partner's role: - to purchase and resell the product to clinics or laboratories under the distribution agreement; - to promote and represent the companie's products to the new markets under the commercial agency agreement.